Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 2/2021

19.08.2020 | Original Article

Disease Knowledge and General Self-Efficacy Among Adolescents with Thalassemia Major and Their Parents’ Perspective

verfasst von: Rekha Kharyal, Vanita Kumari, V. T. Mrunalini, Monika Naik, Poonam Joshi, Tulika Seth

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Thalassemia major can affect physical, psycho-social and economic life of patients and their parents. The aim of the study was to assess the disease knowledge and general self-efficacy among adolescents with Thalassemia major and their parents’ perspective with a view to develop an informational booklet on thalassemia. In a cross-sectional study 50 adolescents along with 48 parents were recruited from the hematology day care centre of a tertiary care facility. Ethical clearance from institute ethics committee, written informed consent from parent and assent from the adolescent were taken. Consecutive participants those who consented were enrolled in the study. Adolescents between the age group of 10–18 years, and their parents completed the self-developed subject data sheet, knowledge questionnaire and standardized general self-efficacy tools. The mean knowledge scores of the adolescent and their parents related to thalassemia were 13.9 ± 2.9 and 13.7 ± 3.6 respectively, while the perceived GSE scores of the adolescent along with the parents’ perspective were 30.1 ± 6.1 and 29.3 ± 6.5. Positive correlation between the adolescents’ knowledge with GSE (r = 0.464, p = 0.007) was observed. The knowledge of the adolescents and their parents showed significant association with the education (p = 0.001, p = 0.002) residence (p = 0.04 and p = 0.01) and parents’ employment (p = 0.04). The knowledge of adolescents with thalassemia and their parents is limited. There is need to counsel the adolescents and their parents about the disease and its management in order to improve the GSE of these adolescents.
Literatur
1.
Zurück zum Zitat Quirolo K, Vichinsky E (2016) Sickle cell anemia, thalassemia, and congenital hemolytic anemias. Rossi principle of transfusion medicine, 5th edn Quirolo K, Vichinsky E (2016) Sickle cell anemia, thalassemia, and congenital hemolytic anemias. Rossi principle of transfusion medicine, 5th edn
2.
Zurück zum Zitat Piel FB, Weatherall DJ (2014) The α-thalassemias. N Engl J Med 371(20):1908–1916CrossRef Piel FB, Weatherall DJ (2014) The α-thalassemias. N Engl J Med 371(20):1908–1916CrossRef
5.
Zurück zum Zitat Aessopos A, Farmakis D (2005) Pulmonary hypertension in β-thalassemia. Ann NY Acad Sci 1054:342–349CrossRef Aessopos A, Farmakis D (2005) Pulmonary hypertension in β-thalassemia. Ann NY Acad Sci 1054:342–349CrossRef
7.
Zurück zum Zitat Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111:467–473PubMed Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP (2000) Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 111:467–473PubMed
8.
Zurück zum Zitat Odysseas P, Georgios A, Kallisteni F, Markos P, Efstathios G, Georgios T (2004) Glucose metabolism disorders improvement in patients with thalassaemia major after 24–36 months of intensive chelation therapy. Pediatr Endocrinol Rev 2(Suppl 2):279–281 Odysseas P, Georgios A, Kallisteni F, Markos P, Efstathios G, Georgios T (2004) Glucose metabolism disorders improvement in patients with thalassaemia major after 24–36 months of intensive chelation therapy. Pediatr Endocrinol Rev 2(Suppl 2):279–281
9.
Zurück zum Zitat De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M et al (2013) Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metabol 17(1):8–18. https://doi.org/10.4103/2230-8210.107808CrossRef De Sanctis V, Soliman AT, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M et al (2013) Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metabol 17(1):8–18. https://​doi.​org/​10.​4103/​2230-8210.​107808CrossRef
10.
Zurück zum Zitat Hattab FN (2013) Patterns of physical growth and dental development in Jordanian children and adolescents with thalassemia major. J Oral Sci 55(1):71–77CrossRef Hattab FN (2013) Patterns of physical growth and dental development in Jordanian children and adolescents with thalassemia major. J Oral Sci 55(1):71–77CrossRef
11.
Zurück zum Zitat Baraz S, Miladinia M, Mosavinouri E (2016) A comparison of quality of life between adolescences with beta thalassemia major and their healthy peers. Int J Pediatr. 4(1):1195–1204 Baraz S, Miladinia M, Mosavinouri E (2016) A comparison of quality of life between adolescences with beta thalassemia major and their healthy peers. Int J Pediatr. 4(1):1195–1204
12.
Zurück zum Zitat Mostafa S, Ab Elaziz M (2014) Factors affecting compliance plan of thalassemic children and their mothers in outpatient clinic at Zagazig University Hospitals. J Biol Agric Healthc 4(3):42–52 Mostafa S, Ab Elaziz M (2014) Factors affecting compliance plan of thalassemic children and their mothers in outpatient clinic at Zagazig University Hospitals. J Biol Agric Healthc 4(3):42–52
14.
Zurück zum Zitat Dehkordi AH, Heydarnejad MS (2008) Effect of booklet and combined method on parents’ awareness of children with β-thalassemia major disorder. J Pak Med Assoc 58(9):485–487PubMed Dehkordi AH, Heydarnejad MS (2008) Effect of booklet and combined method on parents’ awareness of children with β-thalassemia major disorder. J Pak Med Assoc 58(9):485–487PubMed
15.
Zurück zum Zitat Wojciechowski EA, Hurtig A, Dorn L (2002) A natural history study of adolescents and young adults with sickle cell disease as they transfer to adult care: a need for case management services. J Pediatr Nurs 17:18–27CrossRef Wojciechowski EA, Hurtig A, Dorn L (2002) A natural history study of adolescents and young adults with sickle cell disease as they transfer to adult care: a need for case management services. J Pediatr Nurs 17:18–27CrossRef
Metadaten
Titel
Disease Knowledge and General Self-Efficacy Among Adolescents with Thalassemia Major and Their Parents’ Perspective
verfasst von
Rekha Kharyal
Vanita Kumari
V. T. Mrunalini
Monika Naik
Poonam Joshi
Tulika Seth
Publikationsdatum
19.08.2020
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 2/2021
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01335-3

Weitere Artikel der Ausgabe 2/2021

Indian Journal of Hematology and Blood Transfusion 2/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.